Actively Recruiting
EUS Guided Portal-systemic Pressure Gradient Measurement
Led by Chinese University of Hong Kong · Updated on 2026-03-20
30
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Portal hypertension is characterised by an increased portal pressure gradient (PPG), that is the difference in pressure between the portal vein and the inferior vena cava (IVC). Portal hypertension is a consequence of cirrhosis resulting from chronic hepatitis. Patients with portal hypertension are at risk of developing complications including oesophageal or gastric varices, variceal bleeding, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy and mortality. Albeit its clinical significance, direct measurement of portal venous pressure to document portal hypertension has traditionally been difficult. The portal vein pressure can be measured by transhepatic or transvenous methods but the procedure carries a risk of intra-peritoneal bleeding. Furthermore, the IVC pressure measurement requires further transjugular catheterisation. Hence, the technique is rarely used. Currently, the gold standard in measurement of portal hypertension is via measurement hepatic venous pressure gradient (HVPG). The HVPG has been shown to correlate with risk of clinical decompensation, development of varices, hepatocellular carcinoma, variceal bleeding, spontaneous bacterial peritonitis and mortality. Nevertheless, the technique has a low acceptance rate amongst patients and it may not be available even in tertiary medical centres. Recently, the use of EUS-guided approach for measurement of portal pressure gradient (PPGM) has been shown to be feasible. The technical success rate was 100% and no adverse events were reported. Measurements obtained with the EUS approach was shown to correlate excellently with clinical parameters of portal hypertension including presence of varices, portal hypertensive gastropathy and thrombocytopenia. Furthermore, the procedure could be performed at the same time of screening oesophagogastroduodenoscopy (OGD), that is frequently required for variceal screening in this group of patients. Hence, the aim of the current study is to investigate the feasibility of EUS-PPGM and correlate the risk of developing complications with the PPGM in patients that are suffering from chronic hepatitis.
CONDITIONS
Official Title
EUS Guided Portal-systemic Pressure Gradient Measurement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suffering from chronic hepatitis induced cirrhosis
- Informed consent available
You will not qualify if you...
- Child-Pugh Class C
- Uncorrected platelet count less than 50,000
- INR greater than 1.5 (natural)
- Previous transjugular intrahepatic or surgical portosystemic shunt
- Portal vein thrombosis
- Anatomic alterations of hepatic vasculature preventing access to portal or hepatic veins
- History of spontaneous bacterial peritonitis within the previous three months
- Portopulmonary hypertension
- Cardiac decompensation
- Evidence of active gastrointestinal bleeding
- Ascites volume preventing apposition of gastrointestinal tract and liver in needle path
- Presence of gastric or duodenal ulcers, dieulafoy's lesion, or cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese University of Hong Kong
Hong Kong, Hong Kong, China
Actively Recruiting
Research Team
A
Anthony Y Teoh, FRCSEd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here